Edgewise Therapeutics, Inc. - Common Stock, $0.0001 par value per share (EWTX)
CUSIP: 28036F105
Q3 2024 13F Holders as of 30 Sep 2024
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Shares outstanding
- 105,503,387
- Total 13F shares
- 101,289,495
- Share change
- -1,030,255
- Total reported value
- $2,703,865,523
- Put/Call ratio
- 19%
- Price per share
- $26.69
- Number of holders
- 174
- Value change
- -$12,073,061
- Number of buys
- 106
- Number of sells
- 59
Quarterly Holders Quick Answers
What is CUSIP 28036F105?
CUSIP 28036F105 identifies EWTX - Edgewise Therapeutics, Inc. - Common Stock, $0.0001 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 28036F105:
Top shareholders of EWTX - Edgewise Therapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
|
Company |
14%
|
15,021,721
|
$270,541,195 | — | 30 Jun 2024 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
8.4%
|
8,909,091
|
$160,452,729 | — | 30 Jun 2024 | |
| Novo Holdings A/S |
13F
3/4/5
|
Company · 10%+ Owner |
6%
|
6,344,430
|
$114,263,184 | — | 30 Jun 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
5.7%
|
6,015,711
|
$108,342,955 | — | 30 Jun 2024 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
5.5%
|
5,840,059
|
$105,179,463 | — | 30 Jun 2024 | |
| FMR LLC |
13F
|
Company |
4.5%
|
4,780,563
|
$86,097,933 | — | 30 Jun 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.3%
|
4,508,166
|
$81,192,069 | — | 30 Jun 2024 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
3.5%
|
3,731,067
|
$67,196,517 | — | 30 Jun 2024 | |
| Cormorant Asset Management, LP |
13F
|
Company |
2.8%
|
3,006,534
|
$54,147,677 | — | 30 Jun 2024 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
2.7%
|
2,874,586
|
$51,771,294 | — | 30 Jun 2024 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
2.5%
|
2,607,299
|
$46,928,267 | — | 30 Jun 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
2.2%
|
2,349,174
|
$42,308,624 | — | 30 Jun 2024 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
2.2%
|
2,325,449
|
$41,881,336 | — | 30 Jun 2024 | |
| TCG Crossover Management, LLC |
13F
|
Company |
2.2%
|
2,272,728
|
$40,931,831 | — | 30 Jun 2024 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
1.8%
|
1,856,417
|
$33,434,070 | — | 30 Jun 2024 | |
| VR Adviser, LLC |
13F
|
Company |
1.7%
|
1,818,182
|
$32,745,458 | — | 30 Jun 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.6%
|
1,672,653
|
$30,130,154 | — | 30 Jun 2024 | |
| STATE STREET CORP |
13F
|
Company |
1.6%
|
1,665,095
|
$29,988,361 | — | 30 Jun 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.5%
|
1,622,741
|
$29,225,566 | — | 30 Jun 2024 | |
| New Leaf Venture Partners, L.L.C. |
13F
|
Company |
1.5%
|
1,553,661
|
$27,981,435 | — | 30 Jun 2024 | |
| VIKING GLOBAL INVESTORS LP |
13F
|
Company |
1.4%
|
1,481,146
|
$26,675,439 | — | 30 Jun 2024 | |
| Bellevue Group AG |
13F
|
Company |
1.4%
|
1,428,929
|
$25,735,011 | — | 30 Jun 2024 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.2%
|
1,260,392
|
$22,699,660 | — | 30 Jun 2024 | |
| EcoR1 Capital, LLC |
13F
|
Company |
1.2%
|
1,250,385
|
$22,519,434 | — | 30 Jun 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.1%
|
1,145,506
|
$20,630,563 | — | 30 Jun 2024 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.82%
|
860,067
|
$15,489,815 | — | 30 Jun 2024 | |
| Artal Group S.A. |
13F
|
Company |
0.77%
|
811,718
|
$14,619,041 | — | 30 Jun 2024 | |
| MPM BioImpact LLC |
13F
|
Company |
0.7%
|
740,661
|
$13,339,305 | — | 30 Jun 2024 | |
| Granahan Investment Management, LLC |
13F
|
Company |
0.67%
|
710,723
|
$12,800,121 | — | 30 Jun 2024 | |
| Opaleye Management Inc. |
13F
|
Company |
0.55%
|
580,000
|
$10,445,800 | — | 30 Jun 2024 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.54%
|
574,517
|
$10,347,051 | — | 30 Jun 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.54%
|
571,197
|
$10,287,258 | — | 30 Jun 2024 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.5%
|
528,594
|
$9,519,978 | — | 30 Jun 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.48%
|
508,691
|
$9,161,524 | — | 30 Jun 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.47%
|
493,847
|
$8,894,185 | — | 30 Jun 2024 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
0.45%
|
475,691
|
$8,567,195 | — | 30 Jun 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.44%
|
467,507
|
$8,417,085 | — | 30 Jun 2024 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.41%
|
436,608
|
$7,863,310 | — | 30 Jun 2024 | |
| Woodline Partners LP |
13F
|
Company |
0.4%
|
421,604
|
$7,593,088 | — | 30 Jun 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.39%
|
415,720
|
$7,487,117 | — | 30 Jun 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.34%
|
362,576
|
$6,529,994 | — | 30 Jun 2024 | |
| S.c.a. Candriam |
13F
|
Individual |
0.31%
|
329,000
|
$5,925,014 | — | 30 Jun 2024 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.3%
|
311,476
|
$5,609,682 | — | 30 Jun 2024 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.28%
|
290,197
|
$5,226,448 | — | 30 Jun 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.26%
|
272,794
|
$4,913,020 | — | 30 Jun 2024 | |
| KENNEDY CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.26%
|
272,071
|
$4,899,999 | — | 30 Jun 2024 | |
| STEMPOINT CAPITAL LP |
13F
|
Company |
0.26%
|
271,057
|
$4,881,737 | — | 30 Jun 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.25%
|
268,712
|
$4,839,503 | — | 30 Jun 2024 | |
| ExodusPoint Capital Management, LP |
13F
|
Company |
0.25%
|
268,143
|
$4,829,000 | — | 30 Jun 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.24%
|
249,974
|
$4,502,040 | — | 30 Jun 2024 |
Institutional Holders of Edgewise Therapeutics, Inc. - Common Stock, $0.0001 par value per share (EWTX) as of Q3 2024
As of 30 Sep 2024,
Edgewise Therapeutics, Inc. - Common Stock, $0.0001 par value per share (EWTX) was held by
174 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
101,289,495 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, RA CAPITAL MANAGEMENT, L.P., BlackRock, Inc., BAKER BROS. ADVISORS LP, Novo Holdings A/S, JANUS HENDERSON GROUP PLC, VANGUARD GROUP INC, Cormorant Asset Management, LP, Frazier Life Sciences Management, L.P., and Paradigm Biocapital Advisors LP.
This page lists
174
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
138
Q3 2024 holders
174
Holder diff
36
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 Value $ | Q3 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.